Time Course Profile of Adverse Events of Interest and Serious Adverse Events With Darolutamide in the ARAMIS Trial

被引：0

作者：

Grabbert, Markus ^{[1
]}

Gratzke, Christian ^{[1
]}

Fizazi, Karim ^{[2
]}

Shore, Neal ^{[3
]}

Smith, Matthew ^{[4
]}

Feyerabend, Susan ^{[5
]}

Carles, Joan ^{[6
]}

Lebret, Thierry ^{[7
]}

Vjaters, Egils ^{[8
]}

Werbrouck, Patrick ^{[9
]}

Miskic, Marina ^{[10
]}

Schmall, Anja ^{[11
]}

Le Berre, Marie Aude ^{[12
]}

Borghesi, Gustavo ^{[13
]}

Verholen, Frank ^{[14
]}

机构：

[1] Univ Hosp Freiburg, Freiburg, Germany

[2] Univ Paris Saclay, Inst Gustave Roussy, Villejuif, France

[3] Carolina Urol Res Ctr, Myrtle Beach, SC USA

[4] Massachusetts Gen Hosp, Boston, MA USA

[5] Studienpraxis Urol, Nuertingen, Germany

[6] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol, Barcelona, Spain

[7] Hop Foch, Suresnes, France

[8] P Stradins Clin Univ Hosp, Riga, Latvia

[9] AZ Groeninge, Kortrijk, Belgium

[10] Bayer Consumer Care AG, Basel, Switzerland

[11] Bayer Vital GmbH, Leverkusen, Germany

[12] Bayer Healthcare SAS, Loos, France

[13] Bayer AG, Berlin, Germany

[14] Bayer Healthcare SAS, Basel, Switzerland

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

327

引用

页码：105 / 105

页数：1

共 50 条

[1] Time Course Profile of Adverse Events of Interest and Serious Adverse Events With Darolutamide in the ARAMIS Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 13 - 14
[2] Time course profile of adverse events of interest and serious adverse events with darolutamide in the ARAMIS trial
Gratzke, C. J.
Fizazi, K.
Shore, N. D.
Smith, M. R.
Feyerabend, S.
Grabbert, M.
Carles, J.
Lebret, T.
Vjaters, E.
Werbrouck, P.
Miskic, M.
Ortiz, J.
Schmall, A.
Le Berre, M. A.
Verholen, F.
ANNALS OF ONCOLOGY, 2021, 32 : S664 - S664
[3] SURVEILLANCE OF ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS DURING VACCINE TRIAL: EXPERIENCE OF CVD MALI
Doumbia, Moussa
Haidara, Fadima Cheick
Diallo, Fatoumata
Coulibaly, Flanon
Coulibaly, Adama
Tapia, Milagritos D.
Sow, Samba O.
Kotloff, Karen
Levine, Myron M.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 97 (05): : 362 - 362
[4] Serious adverse events with infliximab: Analysis of spontaneously reported adverse events
Hansen, Richard A.
Gartlehner, Gerald
Powell, Gregory E.
Sandler, Robert S.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (06) : 729 - 735
[5] Remimazolam and serious adverse events
Kempenaers, Sander
Hansen, Tom G.
van de Velde, Marc
EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 2023, 40 (11) : 841 - 853
[6] Serious neurological adverse events with ivermectin
Reactions Weekly, 2018, 1692 (1) : 5 - 5
[7] Antipsychotic serious adverse events in context
Suzuki, Takefumi
LANCET PSYCHIATRY, 2019, 6 (09): : 717 - 718
[8] The International Serious Adverse Events Consortium
Arthur L. Holden
Jorge L. Contreras
Sally John
Matthew R. Nelson
Nature Reviews Drug Discovery, 2014, 13 : 795 - 796
[9] Serious Neurological Adverse Events of Ceftriaxone
Lacroix, Clemence
Bera-Jonville, Annie-Pierre
Montastruc, Francois
Velly, Lionel
Micallef, Joelle
Guilhaumou, Romain
ANTIBIOTICS-BASEL, 2021, 10 (05):
[10] Serious adverse CV events with varenicline
Reactions Weekly, 2011, 1360 (1) : 5 - 5

← 1 2 3 4 5 →